George F. Tidmarsh

George F. Tidmarsh is a declared insider at 5 companies (board member); the most frequent names are La Jolla Pharmaceutical Co, Revelation Biosciences, Inc. and Spectrum Pharmaceuticals Inc. Over a trading history stretching from 15 July 2010 to 11 February 2025, the count stands at 64 filings.

In open-market terms, that means 33 purchases worth €970k on one side and 7 sales worth €40k on the other. The net balance comes to €930k on the buying side. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 20 share grants and 2 option exercises.

Half of the purchases are above €16k and half below. On 10 out of 18 purchases, another insider of the same company was buying within the same 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. For 8 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 0% of cases, with a median move of -67.9%. These figures describe past trades and do not predict future prices.

The newest entry dates from 13 February 2025: a share grant of €680, in Revelation Biosciences, Inc. The last insider purchase was made public on 19 April 2023, 1,284 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.